What are the next steps in evaluating an 82-year-old woman with microscopic hematuria and negative cystoscopy and computed tomography (CT) scans?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Microscopic Hematuria in an 82-Year-Old Woman with Negative Workup

For an 82-year-old woman with microscopic hematuria and negative cystoscopy and CT scans, a repeat urinalysis within 12 months is recommended to ensure safety, with persistent microscopic hematuria warranting consideration of additional evaluation. 1

Risk Assessment and Follow-up Strategy

Initial Considerations

  • Age >60 years is a significant risk factor for urologic malignancy 1, 2
  • Despite negative initial evaluation, continued surveillance is important due to:
    • Age-related increased risk of malignancy
    • Small possibility of missed pathology on initial workup

Recommended Next Steps

  1. Repeat Urinalysis within 12 months

    • Primary safety measure recommended by AUA/SUFU guidelines 1
    • If negative: Consider case-by-case decision for future monitoring
    • If persistent microscopic hematuria: Proceed with additional evaluation
  2. For Persistent Microscopic Hematuria on Follow-up

    • Consider shared decision-making regarding need for additional evaluation 1
    • Options include:
      • Additional imaging of urinary tract 1
      • Consideration of urine cytology if irritative voiding symptoms or risk factors for carcinoma in situ exist 1

Additional Considerations

Upper Tract Evaluation

  • If patient has family history of renal cell carcinoma or genetic renal tumor syndrome:
    • Additional upper tract imaging is warranted regardless of risk category 1
    • Options include CT urogram, MR urogram, or retrograde pyelography 1

Role of Urine-Based Markers

  • Routine use of urine cytology or urine-based tumor markers is not recommended for initial evaluation or as adjunctive tests with normal cystoscopy 1
  • Exception: Consider urine cytology for patients with persistent microscopic hematuria who have irritative voiding symptoms or risk factors for carcinoma in situ 1

Risk of Malignancy After Negative Workup

  • Studies show low incidence of malignancies after an initial negative evaluation 1
  • However, in one study, 1.2% of patients with persistent or recurrent microscopic hematuria were found to have bladder tumors on repeat evaluation 1

Important Caveats

  • Do not attribute microscopic hematuria solely to anticoagulant therapy without proper evaluation 2
  • Do not assume hematuria is due to UTI without supporting evidence of infection 2
  • If the patient develops gross hematuria, significant increase in degree of microscopic hematuria, or new urologic symptoms, prompt further evaluation is required 1
  • Consider nephrology referral if there are signs of kidney disease (proteinuria, elevated creatinine, etc.) 2

Follow-up Schedule

  • Initial repeat urinalysis: Within 12 months
  • If persistent microscopic hematuria: Consider repeat evaluation at 6,12,24, and 36 months based on risk stratification 2

This approach balances the small risk of missed pathology against the anxiety, cost, inconvenience, and risks of ongoing monitoring and repeated investigations.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Evaluation and Management of Hematuria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.